Lv6
2110 积分 2023-11-10 加入
POS0114 A PLACEBO-CONTROLLED PHASE 1 STUDY IN HEALTHY ADULT VOLUNTEERS OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ALPN-303, A POTENT DUAL BAFF/APRIL ANTAGONIST, FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS
13小时前
求助中
Membranous nephropathy
27天前
已完结
Angiogenesis and Pancreatic Cancer: Novel Approaches to Overcome Treatment Resistance
1个月前
已完结
Pancreatic cancer
1个月前
已完结
Interleukin-1 receptor accessory protein (IL-1RAP): A magic bullet candidate for immunotherapy of human malignancies
1个月前
已完结
Role of ROCK2 inhibitors in the treatment of chronic graft-versus-host disease
2个月前
已完结
Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials
4个月前
已完结
Targeting OX40: rocatinlimab—a novel therapy for atopic dermatitis
4个月前
已完结
Fibroblast heterogeneity in 2025
4个月前
已完结
A new member of the IL-1 receptor family highly expressed in hippocampus and involved in X-linked mental retardation
4个月前
已完结
皖公网安备34019202002308
